The α2,3-selective potentiators of GABAA receptors, KRM-II-81 and MP-III-80, produce anxiolytic-like effects and block chemotherapy-induced hyperalgesia in mice without tolerance development.

Pharmacology, Biochemistry, and Behavior
A BiggerstaffJeffrey M Witkin

Abstract

Opiate analgesics are one of the treatment options for severe chronic pain, including late-stage cancer, chronic back pain and other disorders. The recent resurgence in opioid overdose has highlighted the serious need for alternative medicines for pain management. While a role for potentiators of α2/3-containing GABAA receptors in the modulation of pain has been known for several years, advancements in this area required data from selective compounds. KRM-II-81(5-(8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3- yl)oxazole) and analogs selectively potentiate GABAA receptors containing α2/3 subunits and have recently been shown to attenuate pain behaviors in several acute and chronic pain models in rodents. The present study was designed to ascertain whether KRM-II-81 and the structural analog MP-III-80 (3-ethyl-5-(8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)-1,2,4-oxadiazole) would block chemotherapeutic agent paclitaxel-induced pain in male, C57BL/6 mice. Both compounds significantly inhibited pain behaviors evoked by cold and tactile stimulation in paclitaxel-treated mice as did the neuropathic pain drug gabapentin. Subchronic dosing for 22 days with KRM-II-81 and MP-III-80 demon...Continue Reading

References

Jan 1, 1985·Neuroscience and Biobehavioral Reviews·H C Rosenberg, T H Chiu
Aug 3, 1984·European Journal of Pharmacology·D L Hammond, E J Drower
Jul 30, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Carolien van RijnsoeverFlorence Crestani
Jan 22, 2005·Current Opinion in Pharmacology·Keith A Wafford
Dec 21, 2006·Advances in Pharmacology·S J Enna, Kenneth E McCarson
Sep 20, 2007·Expert Opinion on Drug Safety·Neena I MarupudiHenry Brem
Oct 1, 2009·The Journal of Pharmacology and Experimental Therapeutics·Nancy A AtorGerard R Dawson
Feb 12, 2010·Nature·Kelly R TanChristian Lüscher
Sep 3, 2011·Journal of Pain & Palliative Care Pharmacotherapy·Kevin D Jordan, Akiko Okifuji
Oct 6, 2011·Anaesthesia and Intensive Care·C A HuxtableP E MacIntyre
Apr 24, 2012·The Journal of Comparative Neurology·Jolly PaulJean-Marc Fritschy
Aug 14, 2012·Journal of Psychoactive Drugs·Mel Pohl, Logan Smith
Nov 5, 2013·The Medical Clinics of North America·Joseph Salama-Hanna, Grace Chen
Jun 13, 2014·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Louis-Etienne LorenzoYves De Koninck
Feb 1, 2015·Advances in Pharmacology·Hanns Ulrich ZeilhoferMario A Acuña
Oct 6, 2015·Modern Trends in Pharmacopsychiatry·Borwin Bandelow
Nov 5, 2016·Expert Opinion on Emerging Drugs·Nikolaos Papanas, Dan Ziegler
Nov 18, 2016·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Alex EtlinAllan I Basbaum
Oct 1, 2017·British Journal of Pharmacology·Molly S CroweSteven G Kinsey
Oct 2, 2017·Life Sciences·Yun-Yi YanYun-Man Li
Jan 29, 2018·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Judy NeeAnthony Lembo
Sep 27, 2018·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Rita J Valentino, Nora D Volkow
Sep 5, 2019·The Journal of Pharmacology and Experimental Therapeutics·Nathan P CoussensKurt Rasmussen
Feb 28, 2020·Journal of Pain Research·Jin Young LeeHue Jung Park

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.